Has anyone dealt with lyophilization process for peptides?

PeptideChemSF said:

The shortage clause is the answer to the second question and it is a subtraction rather than an addition.

Pushing back on PeptideChemSF here. A research-chemical supplier selling lyophilised powder labelled research use only is not compounding and is not claiming to. It is a different legal universe with no pharmacy oversight, no patient relationship and no content guarantee, and conflating the two in these threads helps nobody.

Happy to go further on any of that.

Dr.AddMedPHL said:

Two pharmacies quoted me last year, one describing itself as 503A and one as 503B, and I assumed 503B just meant bigger until both stopped within…

Compounding pharmacy customer here with experience relevant to compounded supply.

I've ordered from 2 different compounding pharmacies over the past 2 years. The quality variation is real — purity ranged from 94% to 101% of label claim based on independent Janoshik testing.

My current compounder (a 503B facility) has been consistently 98-101% purity across 10 orders. I pay $125/month vs $1,355 for brand. The savings are substantial and the product is equivalent in my experience.

Re: compounded supply — this applies whether you're using brand or compounded. The clinical principles are the same.

pete_manc_UK said:

A research-chemical supplier selling lyophilised powder labelled research use only is not compounding and is not claiming to.

503A vs 503B compounding pharmacies for compounded supply — this distinction matters enormously:

I strongly recommend 503B facilities. The FDA oversight and cGMP requirements mean more consistent product quality.

Following on from LarryQC_SD — and this may be the naive question:

What actually distinguishes 503A from 503B, in terms of what each may make and from what starting material?

Reporting back.

The bulks-list asymmetry was the piece I had missed entirely. It explains why one of my two pharmacies is still arguing it can supply and the other simply stopped.